arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ImmunityBio, Inc.

IBRX
$7.63 ▲ +0.33 (+4.45%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
14 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

ImmunityBio, Inc. faces fundamental challenges. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $7.0B
Dividend Yield
Revenue Growth 668.3%
Op. Margin -226.0%
ROIC 51.1%
FCF / Share $-0.34
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$113.29M
↑ +668.3%
Net Income Profit after all expenses
$-351.40M
↑ +15.0%
FCF / Share Free cash flow per share
$-0.34
↑ +41.2%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
98
Financial Health
38
Cash Quality
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters